Estimating Inhaled Corticosteroid Exposure from Short-Acting β2-Agonist–Inhaled Corticosteroid Rescue
Copyright policy )Estimating Inhaled Corticosteroid Exposure from Short-Acting β2-Agonist–Inhaled Corticosteroid Rescue
Njira Lugogo,1 Ileen Gilbert,2 Michael Pollack,2 Hitesh Gandhi,2 Joseph Tkacz,3 Miguel J Lanz4 1Department of Medicine, Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, MI, USA; 2BioPharmaceuticals Medical, AstraZeneca, Wilmington, DE, USA; 3Inovalon, Bowie, MD, USA; 4Allergy and Asthma, AAADRS Clinical Research Center, Coral Gables, FL, USACorrespondence: Michael Pollack, BioPharmaceuticals Medical, AstraZeneca, 1800 Concord Pike, Wilmington, DE, 19850, USA, Tel +1-302-886-1253, Email Michael.pollack1@astrazeneca.com
- AstraZeneca (United States) United States
- University of Michigan–Flint United States
- Center for Clinical Research (United States) United States
Research Letter, short-acting β2-agonist–inhaled corticosteroid, Immunologic diseases. Allergy, RC581-607, inhaler
Research Letter, short-acting β2-agonist–inhaled corticosteroid, Immunologic diseases. Allergy, RC581-607, inhaler
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).0 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average
Citations provided by BIP!Popularity provided by BIP!